I-O Optimise: Aims and objectives

The insights generated from I-O Optimise will complement clinical trial evidence, thus providing information that is not only critical for stakeholders, but also that may not be achievable through other routes. The real-world insights generated aim to improve patient outcomes and aid in the selection of cost-effective therapies that best meet patients’ expectations.

I-O Optimise aims to generate real-world insights about the management of lung cancers* in order to:

  • Help drive improved long-term clinical and safety outcomes
  • Inform on the evolving role of biomarkers in treatment decisions and in the assessment of treatment patterns
  • Identify factors that may influence resource utilisation and patient care

I-O Optimise aims to deliver valuable insights that may help:

  • Oncologists and other healthcare professionals to select appropriate therapies based on informed decisions
  • Patients to be better informed about treatment choices and ultimately to achieve better outcomes
  • Researchers to understand what additional information should be gathered when conducting clinical trials and what complementary evidence is lacking
  • Payers and regulators to assess the value of innovative therapies

The delivery of insights began in 2017, with regular updates over the long term as the treatment landscape evolves further. Over time, it should be possible to compare different populations and healthcare systems.

*I-O Optimise will initially generate data for non-small cell lung cancer, small cell lung cancer and mesothelioma.